Document Detail

Shortening baroreflex delay in hypertrophic cardiomyopathy patients -- an unknown effect of β-blockers.
MedLine Citation:
PMID:  23126403     Owner:  NLM     Status:  MEDLINE    
AIMS: Hypertrophic cardiomyopathy (HCM) is characterized by left ventricular hypertrophy and impaired diastolic and systolic function. Abnormal sympathetic-parasympathetic balance is a potential stimulus for left ventricular hypertrophy in HCM patients. β-Blockers are routinely used in HCM for their strong negative inotropic effect; however, these drugs also influence the sympathetic-parasympathetic balance. This study aimed to determine the autonomic control of the cardiovascular system and the autonomic effects of β-blockers in HCM patients treated or untreated with β-blockers.
METHODS: Among 51 HCM outpatients (18-70 years old; 29 men) there were 19 individuals with no medication and 32 subjects treated with a β-blocker. Fourteen age- and gender-matched (23-70 years old; nine men) healthy volunteers were enrolled in the control group. Continuous, non-invasive finger blood pressure was recorded during supine rest for 30 min. Autonomic regulation of the cardiovascular system was measured by heart rate variability and spontaneous baroreflex function (cross-correlation sequence method).
RESULTS: The mean pulse interval, time domain and spectral measures of heart rate variability and baroreflex sensitivity were comparable between HCM patients, treated or not with β-blockers, and the control group. However, the delay of the baroreflex was significantly longer in HCM patients who were not treated with β-blockers [2.0 (1.6-2.3) s] in comparison with HCM patients receiving β-blockers [1.4 (1.1-1.8) s; P = 0.0072] or control subjects [1.2 (0.8-1.8) s; P = 0.0025]. This delay did not differ between HCM patients treated with β-blockers and the control group.
CONCLUSIONS: Hypertrophic cardiomyopathy not treated with β-blockers is accompanied by prolonged baroreflex delay. The use of β-blockers normalizes this delay.
Agnieszka Katarzynska-Szymanska; Romuald Ochotny; Zofia Oko-Sarnowska; Hanna Wachowiak-Baszynska; Tomasz Krauze; Jaroslaw Piskorski; Adrian Gwizdala; Przemyslaw Mitkowski; Przemyslaw Guzik
Related Documents :
25487873 - Adenoids of patients with mucopolysaccharidoses demonstrate typical alterations.
20395143 - Lateralized infarction in cerebral air embolism due to patient positioning.
11734913 - Evaluation of (pre-)malignant colonic abnormalities: endoscopic validation of fdg-pet f...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  British journal of clinical pharmacology     Volume:  75     ISSN:  1365-2125     ISO Abbreviation:  Br J Clin Pharmacol     Publication Date:  2013 Jun 
Date Detail:
Created Date:  2013-05-22     Completed Date:  2014-01-17     Revised Date:  2014-06-03    
Medline Journal Info:
Nlm Unique ID:  7503323     Medline TA:  Br J Clin Pharmacol     Country:  England    
Other Details:
Languages:  eng     Pagination:  1516-24     Citation Subset:  IM    
Copyright Information:
© 2012 The Authors. British Journal of Clinical Pharmacology © 2012 The British Pharmacological Society.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Adrenergic beta-1 Receptor Antagonists / therapeutic use*
Baroreflex / drug effects*
Bisoprolol / therapeutic use
Cardiomyopathy, Hypertrophic / drug therapy*
Case-Control Studies
Heart Rate / drug effects*
Metoprolol / therapeutic use
Middle Aged
Time Factors
Young Adult
Reg. No./Substance:
0/Adrenergic beta-1 Receptor Antagonists; GEB06NHM23/Metoprolol; Y41JS2NL6U/Bisoprolol

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Enhanced human endothelial progenitor cell adhesion and differentiation by a bioinspired multifuncti...
Next Document:  Ion beam polishing for three-dimensional electron backscattered diffraction.